Cargando…
Aberrantly glycosylated integrin α3β1 is a unique urinary biomarker for the diagnosis of bladder cancer
Bladder cancer (BC) is the most common malignancy of the urinary tract. We developed a new and ELISA kit for detecting aberrantly glycosylated integrin α3β1 (AG31) in human urine. We analysed urine samples (n=408) of patients with BC, renal cell carcinoma (RCC), prostate cancer (PC), cystitis, nephr...
Autores principales: | Jin, Di, Zhang, Ruiyun, Chen, Haige, Li, Chong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346044/ https://www.ncbi.nlm.nih.gov/pubmed/32534450 http://dx.doi.org/10.18632/aging.103297 |
Ejemplares similares
-
Roles of Integrin α6β4 Glycosylation in Cancer
por: Kariya, Yoshinobu, et al.
Publicado: (2017) -
N-Glycosylation of integrin α5 acts as a switch for EGFR-mediated complex formation of integrin α5β1 to α6β4
por: Hang, Qinglei, et al.
Publicado: (2016) -
Aberrant glycosylation associated with enzymes as cancer biomarkers
por: Meany, Danni L, et al.
Publicado: (2011) -
Selective inhibition of integrin αvβ6 leads to rapid induction of urinary bladder tumors in cynomolgus macaques
por: Guffroy, Magali, et al.
Publicado: (2022) -
Aberrant Glycosylation as Biomarker for Cancer: Focus on CD43
por: Tuccillo, Franca Maria, et al.
Publicado: (2014)